Biotransformation and mass balance of tipranavir, a nonpeptidic protease inhibitor, when co-administered with ritonavir in Sprague-Dawley rats

Journal of Pharmacy and Pharmacology

Volumn 59, Issue 9, 2007, Pages 1223-1233

  Macha, Sreeraj ^a   Chen, Linzhi ^a   Norris, Stephen H ^a   Philip, Elsy ^a   Mao, Yanping ^a   Silverstein, Helga ^a   Struble, Craig ^b   Beers, Wendy ^b  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b 206 Carnegie Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; RITONAVIR; TIPRANAVIR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BILE DUCT; BLOOD SAMPLING; CONTROLLED STUDY; DATA ANALYSIS; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG TRANSFORMATION; DRUG URINE LEVEL; FECES; FEMALE; MALE; NONHUMAN; RADIOACTIVITY; RAT; SPRAGUE DAWLEY RAT; URINALYSIS; URINARY EXCRETION;

ABSORPTION; ADMINISTRATION, ORAL; ANIMALS; ANTI-HIV AGENTS; BILE; BIOTRANSFORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HIV PROTEASE INHIBITORS; INJECTIONS, INTRAVENOUS; MALE; OXIDATION-REDUCTION; PYRIDINES; PYRONES; RATS; RATS, SPRAGUE-DAWLEY; RITONAVIR; SEX FACTORS; TISSUE DISTRIBUTION;

EID: 34548462177     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.59.9.0006     Document Type: Article

References (24)

1. Back, N. K. T., van Wijk, A., Remmerswaal, D., van Monfort, M., Nijhuis, M., Schuurman, R., Boucher, C. A. B. (2000) In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS 14: 101-102
2. Barry, M., Gibbons, S., Back, D., Mulcahy, F. (1997) Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin. Pharmacokinet. 32: 194-209
3. Cahn, P., RESIST-2 Study Team (2004) 24-week data from RESIST-2: Phase 3 study of the efficacy and safety of either tipranavir/ritonavir (TPV/r) or an optimized ritonavir (RTV)-boosted standard-of-care (SOC) comparator PI (CPI) in a large randomized multicentre trial in treatment-experienced HIV+ patients. 7th International Congress on Drug Therapy in HIV Infection, November 14-18, Glasgow, UK. Abstract PL 14.3
4. Cooper, C. L., van Heeswijk, R. P., Gallicano, K., Cameron, D. W. (2003) A review of low-dose ritonavir in protease inhibitor combination therapy. Clin. Infect. Dis. 36: 1585-1592
5. Ernest, C. S., Hall, S. D., Jones, D. R. (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J. Pharmacol. Exp. Ther. 312: 583-591
6. Hicks, C. (2004) RESIST-1: a phase 3 randomized, controlled, open-label multicenter trial comparing tipranavir/ritonavir (TPV/r) to an optimized comparator protease inhibitor/r (CPI/r) regimen in antiretroviral (ARV) experienced patients: 24-week data. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 31-November 2, 2004, Washington, DC. Presentation H-1137a
7. Hoetelmans, R. M., Reijers, M. H., Weverling, G. J., ten Kate, R. W., Wit, F. W., Mulder, J. W., Weigel, H. M., Frissen, P. H., Roos, M., Jurriaans, S., Schuitemaker, H., de Wolf, F., Beijnen, J. H., Lange, J. M. (1998) The effect of plasma drag concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 12: F111-F115
8. Kempf, D. J., Marsh, K. C., Kumar, G., Rodrigues, A. D., Denissen, J. F., McDonald, E., Kukulka, M. J., Hsu, A., Granneman, G. R., Baroldi, P. A., Sun, E., Pizzuti, D., Planner, J. J., Norbeck, D. W., Leonard, J. M. (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41: 654-660
9. Koudriakova, T., Iatsimirskaia, E., Utkin, I., Gangl, E., Vouros, P., Storozhuk, E., Orza, D., Marinina, J., Gerber, N. (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug. Metab. Dispos. 26: 552-561
10. Kumar, G. N., Dykstra, J., Roberts, E. M., Jayanti, E. M., Hickman, D., Uchic, J., Yao, Y., Surber, B., Thomas, S., Granneman, G. R. (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug. Metab. Dispos. 27: 902-908
11. Kumar, G. N., Jayanti, V. K., Johnson, M. K., Uchic, J., Thomas, S., Lee, R. D., Grabowski, B. A., Sham, H. L., Kempf, D. J., Denissen, J. F., Marsh, K. C., Sun, E., Roberts, S. A. (2004) Metabolism and disposition of the HIV-1 protease inhibitor lopinavir (ABT-378) given in combination with ritonavir in rats, dogs, and humans. Pharm. Res. 21: 1622-1630
12. Larder, B. A., Hertogs, K., Bloor, S., van den Eynde, C., DeCian, W., Wang, Y., Freimuth, W. W., Tarpley, G. (2000) Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14: 1943-1948
13. MacGregor, T., Sabo, J. P., Norris, S. H., Johnson, P., Galitz, L., McCallister, S. (2004) Pharmacokinetic characterization of different dose combinations of co-administered tipranavir and ritonavir in healthy volunteers. HIV Clin. Trials 5: 371-382
14. McCallister, S., Valdez, H., Curry, K., MacGregor, T., Borin, M., Freimuth, W., Wang, Y., Mayers, D. L. (2004) A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients. J. Acquir. Immune. Defic. Syndr. 35: 376-382
15. Monini, P., Sgadari, C., Barillari, G., Ensoli, B. (2003) HIV protease inhibitors: antiretroviral agents with anti-inflammatory, antiangiogenic and anti-tumor activity. J. Antimicrob. Agents. Chemother. 51: 207-211
16. Moyle, G. (2001) Use of HIV protease inhibitors as pharmacoenhancers. AIDS Read 11: 87-98
17. Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., Holmberg, S. D. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338: 853-860
18. Patick, A. K., Potts, K. E. (1998) Protease inhibitors as antiviral agents. Clin. Microbiol. Rev. 11: 614-627
19. Shibata, N., Gao, W., Okamoto, H., Kishida, T., Yoshikawa, Y., Takada, K. (2002) In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats. J. Pharm. Pharmacol. 54: 221-229
20. Thiasrivongs, S., Strohbach, J. W. (1999) Structure-based discovery of tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopolymers 51: 51-58
21. Turner, S. R., Strohbach, J. W., Tommasi, R. A., Aristoff, P. A., Johnson, P. D., Skulnick, H. I., Dolak, L. A., Seost, E. P., Tomich, P. K., Bohanon, M. J., Horng, M. M., Lynn, J. C., Chong, K. T., Hinshaw, R. R., Watenpaugh, K. D., Janakiraman, M. N., Thaisrivongs, S. (1998) Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J. Med. Chem. 41: 3467-3476
22. van Praag, R. M., Wit, F. W., Jurriaans, S., de Wolf, F., Prins, J. M., Lange, J. M. (2002) Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy. AIDS 16: 719-725
23. Walmsley, S., Leith, J., Katlama, C., Arasteh, K., Pierone, G., Blick, G., Lazzarin, A., Johnson, M., Samuels, C., Jones, P., Chaves, R., Quinson, A., Kohlbrenner, V., McCallister, S., Mayers, D. L., Curry, K. (2004) Pharmacokinetics and safety of tipranavir/ritonavir (TPV/r) alone or in combination with saquinavir (SQV), amprenavir (APV), or lopinavir (LPV): interim analysis of BI1182.51. The XV International AIDS Conference, July 11-16; Bangkok, Thailand. Abstract WeOrB1236
24. Yeni, P. G., Hammer, S. M., Hirsch, M. S., Saag, M. S., Schechter, M., Carpenter, C. C., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S., Richman, D. D., Schooley, R. T., Thompson, M. A., Vella, S., Volberding, P. A. (2004) Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA 292: 251-265